Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Sorafenib 22Bevacizumab 15pembrolizumab 10durvalumab 7Nivolumab 7Ipilimumab 6Drug Therapy 6atezolizumab 5Talaporfin 5spartalizumab 4regorafenib 4lenvatinib 4derazantinib 3Ramucirumab 3Photochemotherapy 3Leucovorin 3Injections 3Fluorouracil 3Doxorubicin 3tremelimumab 2toripalimab 2seocalcitol 2relatlimab 2phosphomannopentaose sulfate 2liposomal doxorubicin 2exatecan 2cabozantinib 2brivanib 2Phototherapy 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liver Neoplasms × tasquinimod × Clear all
NCT01743469 2019-01-08

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Ipsen

Phase 2 Completed
201 enrolled 23 charts
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Liver Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡